首页|骨痹方活性成分治疗骨关节炎的抗炎机制研究

骨痹方活性成分治疗骨关节炎的抗炎机制研究

扫码查看
目的 探究骨痹方活性成分治疗骨关节炎的抗炎机制.方法 体外培养正常人软骨细胞,脂多糖(LPS)刺激炎症,,细胞分为对照组(正常培养)、模型组(10 μg·mL-1 LPS)、斛皮素组(10 μg·mL-1 LPS+8 μmol·L-1 槲皮素)、芒柄花素组(10 μg·mL-1 LPS+50 μmol·L-1 芒柄花素)、柚皮苷组(10 µg·mL-1 LPS+10 μmol·L-1 柚皮苷)、川续断皂苷Ⅵ组(10μg·mL-1 LPS+50 μmol·L-1 川续断皂苷Ⅵ)、β-蜕皮甾酮组(10 μg·mL-1 LPS+50 μmol·L-1β-蜕皮甾酮).用细胞计数试剂盒8(CCK8)检测软骨细胞活力,用蛋白质印迹法检测高尔基体外周膜蛋白p65蛋白(P65)、核因子E2相关因子2(Nrf2)核蛋白蛋白表达水平.结果 对照组、模型组、槲皮素组、芒柄花素组、柚皮苷组、川续断皂苷Ⅵ组、β-蜕皮甾酮组的细胞活力分别为(103.10±8.55)%、(62.41±2.35)%、(76.92±1.74)%、(77.01±0.60)%、(80.39±3.06)%、(79.43±0.94)%和(55.20±0.99)%,Nrf2 蛋白相对表达水平分别为 1.00±0.00、1.01±0.09、1.30±0.15、0.91±0.15、1.23±0.25、0.71±0.19、1.51±0.13 和 1.26±0.15,P65蛋白相对表达水平分别为1.00±0.00、2.24±0.85、0.74±0.33、1.49±0.29、0.97±0.06、1.33±0.07、1.67±0.22 和 1.52±0.17,炎症介质iNOS相对表达分别为 1.00±0.00、1.52±0.27、1.07±0.24、1.25±0.12、1.01±0.30、1.44±0.12、1.07±0.18 和 1.11±0.16.上述结果,模型组与对照组比较,差异具有统计学意义(均P<0.05);槲皮素组、芒柄花素组、柚皮苷组的上述指标与模型组比较,在统计学上差异均有统计学意义(P<0.05、P<0.01和P<0.001);川续断皂苷Ⅵ组和β-蜕皮甾酮组的上述指标与模型组比较,在统计学上差异均无统计学意义(均P>0.05).结论 骨痹方活性成分槲皮素、芒柄花素和柚皮苷均能够激活Nrf2-HO-1信号,进而抑制核因子-κB(NF-κB)通路的活化发挥抗炎作用缓解骨关节炎.
Study on the anti-inflammatory mechanism of active ingredients of Gubi Formula in the treatment of osteoarthritis
Objective To explore the anti-inflammatory mechanism of the active ingredients of Gubi Formula in treating osteoarthritis.Methods Normal human chondrocytes were cultured in vitro,and lipopolysaccharide(LPS)stimulated inflammation.The cells were divided into control group(normal culture),model group(10 μg·mL-1 LPS),quercetin group(10 μg·mL-1 LPS+8 μmol·L-1 quercetin),formononetin group(10 μg·mL-1 LPS+50 μmol·L-1 formononetin),naringin group(10 μg·mL-1 LPS+10 μmol·L-1 naringin),asperosaponin Ⅵ group(10 μg·mL-1 LPS+50 pmol·L-1 asperosaponin Ⅵ),β-ecdysterone group(10 μg·mL-1 LPS+50 μmol·L-1β-ecdysterone).Cell counting kit-8(CCK8)was used to detect the viability of chondrocytes.Western blot was used to detect the expression of nuclear factor NF-kappa-B p65 subunit(p65),nuclear factor erythroid 2-related factor 2(Nrf2)nuclear protein.Results The cell viability of control group,model group,quercetin group,formononetin group,naringin group,Dipsacoside Ⅵ group,β-ecdysterone group were(103.10±8.55)%,(62.41±2.35)%,(76.92±1.74)%,(77.01±0.60)%,(80.39±3.06)%,(79.43±0.94)%,(55.20±0.99)%;the relative expression of Nrf2 protein were 1.00±0.00,1.01±0.09,1.30±0.15,0.91±0.15,1.23±0.25,0.71±0.19,1.51±0.13,1.26±0.15;the relative expression of P65 protein were 1.00±0.00,2.24±0.85,0.74±0.33,1.49±0.29,0.97±0.06,1.33±0.07,1.67±0.22,1.52±0.17;the relative expression of inflammatory mediators iNOS were 1.00±0.00,1.52±0.27,1.07±0.24,1.25±0.12,1.01±0.30,1.44±0.12,1.07±0.18,1.11±0.16.The above indexes in quercetin group,formononetin group and naringin group were significantly different from those in model group(P<0.05,P<0.01 and P<0.001).Compared with the model group,there was no significant difference in the above indexes between the Asperosaponin Ⅵ group and theβ-ecdysterone group(all P>0.05).Conclusion The active components of Gubi Formula,including quercetin,mangiferin,and naringin,can activate Nrf2-HO-1 signaling and inhibit the activation of the Nuclear factor-κB(NF-κB)pathway plays an anti-inflammatory role in alleviating osteoarthritis.

active ingredients of gubi formulaosteoarthritisinflammationnuclear factor-κBnuclear factor erythroid 2-related factor 2

丁鹏、田锋祥、许立、葛玉、王福荣、包宇杰、周玲玲

展开 >

南京中医药大学药学院中药药理教研室,江苏南京 210023

骨痹方活性成分 骨关节炎 炎症 核因子-κB 核因子E2相关因子2

国家自然科学基金面上基金资助项目

82174306

2024

中国临床药理学杂志
中国药学会

中国临床药理学杂志

CSTPCD北大核心
影响因子:1.91
ISSN:1001-6821
年,卷(期):2024.40(14)
  • 8